Cell News and Research

RSS

Mirati announces initiation of glesatinib Phase 2 clinical trial in NSCLC patients

Mirati Therapeutics, Inc. today announced that the Phase 2 clinical trial of glesatinib (MGCD265) has commenced. The Company also announced that "glesatinib" is the proposed generic name for MGCD265.

21 Dec 2015

New study improves understanding of metal-based chemotherapy drugs

What is the mechanism of action of metal-based chemotherapy drugs (the most widely used for treating common cancers like testicular or ovarian cancer)? How can we improve their effect and reduce their toxicity? A new study combining experiments and theory has broadened our knowledge of the molecular mechanisms of these active drugs to help experimentalists devising increasingly effective drugs with fewer side effects.

21 Dec 2015

Univercells awarded grant to reduce cost of vaccine manufacturing in the Walloon region

Univercells SA, a company that designs single-use cost-efficient bioprocess solutions for the next generation of biomanufacturing, today announces that it has received a grant from the Walloon region.

21 Dec 2015

TUM scientists develop small molecule that may allow future patient-specific treatment of cancer tumours

Integrins help cells communicate with and adapt to their environment. Also cancer cells depend on their properties to survive and spread throughout the body. Now scientists at the Technical University of Munich have successfully developed a small, highly active molecule that binds to a specific integrin which operates in many types of cancer.

21 Dec 2015

Scientists outline molecular blueprints of tiny cellular 'nanomachine'

Scientists have drawn up molecular blueprints of a tiny cellular ‘nanomachine’, whose evolution is an extraordinary feat of nature, by using one of the brightest X-ray sources on Earth.

21 Dec 2015

TSRI-led study finds potential new therapeutic approach for hard-to-treat breast cancers

Findings from a new study led by scientists from the Florida campus of The Scripps Research Institute (TSRI) suggest a potent new therapeutic approach for a number of hard-to-treat breast cancers.

21 Dec 2015

Bitplane announces launch of Imaris 8.2 with ImarisLineage at ASCB 2015

Bitplane, an Oxford Instruments Company and world leader in 2 to 4D image visualization, analysis and interpretation, has announced the launch of Imaris 8.2 at the American Society for Cell Biology Annual Meeting in San Diego on December 13, 2015.

21 Dec 2015

Adaptimmune begins Phase I/II study of affinity enhanced T-cell therapy targeting MAGE-A10 in NSCLC patients

Adaptimmune Therapeutics plc, a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it has initiated a Phase I/II study of its affinity enhanced T-cell therapy targeting the MAGE-A10 cancer antigen in patients with locally advanced or metastatic (Stage IIIb or IV) non-small cell lung cancer (NSCLC), the most prevalent type of lung cancer representing approximately 85 percent of lung cancers.

21 Dec 2015

Combination therapy can help overcome endocrine resistance in women with advanced breast cancer

Data collected in Japanese and Korean patients included in the global PALOMA3 trial provides evidence that combining palbociclib with fulvestrant is an effective strategy to overcome endocrine resistance in women with hormone receptor positive (HR+), HER2 negative (HER2-) advanced breast cancer.

20 Dec 2015

New discovery may soon make prostate cancer cells easier to destroy

A newly discovered connection between two common prostate cancer treatments may soon make prostate cancer cells easier to destroy. Drugs that could capitalize on the discovery are already in the pipeline, and a clinical trial to test whether the finding could improve treatments for prostate cancer patients could be only a few years away.

20 Dec 2015

Turing Pharmaceuticals emphasizes continued availability of Daraprim

Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on developing and commercializing innovative treatments for serious diseases and conditions, today emphasizes the continued availability of Daraprim and cautions healthcare providers of proposed alternatives to Daraprim.

20 Dec 2015

Variant signs worldwide exclusive license and development agreement with L&F Research

Variant Pharmaceuticals, Inc., an emerging pharmaceutical company focusing on rare diseases and other specialty conditions with limited or sub-optimal therapeutic options, announced today a worldwide exclusive license and development agreement with L&F Research LLC to advance development of Variant's lead product, VAR 200.

20 Dec 2015

Janssen collaborates with Bavarian Nordic to develop, commercialize vaccine for chronic HPV infections

Janssen Pharmaceuticals, Inc. announced today that the company has entered into a definitive collaboration and license agreement with Bavarian Nordic to leverage their MVA-BN technology, jointly with Janssen's own AdVac® technology, in the development and commercialization of a heterologous prime-boost vaccine for the treatment of Human Papillomavirus (HPV) chronic infections which can lead to cancer.

20 Dec 2015

UCL Cancer Institute win $200,000 CytoFLEX Flow Cytometer from Beckman Coulter

An internationally renowned gene therapy research team has won a $200,000 CytoFLEX Flow Cytometer from Beckman Coulter Life Sciences.

From Beckman Coulter Life Sciences - Flow Cytometry 18 Dec 2015

UCLA study may help resolve a neurological mystery

UCLA researchers have found that space-mapping neurons - the GPS system in the brain - have a strong dependence on what is being looked at when triangulating location, a finding that resolves a neurological mystery that has vexed scientists for more than four decades.

18 Dec 2015

Synthetic biomaterial aids in regeneration of skin cells to improve wound healing

Some skin wounds, such as diabetic ulcers, are chronic and may never heal; others, such as burn wounds, are often large and difficult to treat, resulting in pain, infection and scarring. Researchers at the University of California, Los Angeles, funded by the National Institutes of Health, have developed a synthetic biomaterial that fills wounds and aids in regeneration of skin cells, which ultimately improves wound healing.

18 Dec 2015

UB study traces how enigmatic molecules help cancer self-destruct

You've probably never heard of "sphingolipids" before. But these curiously named organic compounds play a vital role in one of humanity's most well-known diseases: cancer.

18 Dec 2015

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited, its drug R&D subsidiary, has initiated SANET-ep, a Phase III sulfatinib (HMPL-012) registration trial in China in patients with extra-pancreatic neuroendocrine tumors ("NETs"), which are all non-pancreatic NETs, including, for example, NETs originating in the lymph, lung and across the gastrointestinal tract.

18 Dec 2015

New test can help detect cancer and diabetes biomarkers in bloodstream

A new test for detecting biomarkers for cancer and diabetes is more than 1000x more detailed and 100% faster than existing methods, new research by the University of Warwick suggests.

18 Dec 2015

Novel drug candidate prevents nerve cell damage in mouse model of Parkinson's disease

A team of scientists at the University of Nebraska Medical Center (UNMC) and Longevity Biotech, Inc., has demonstrated that neuroprotection could be attained in preclinical models by a novel drug candidate that changes immune responses.

18 Dec 2015

Cell News and Research

Mirati announces initiation of glesatinib Phase 2 clinical trial in NSCLC patients

New study improves understanding of metal-based chemotherapy drugs

Univercells awarded grant to reduce cost of vaccine manufacturing in the Walloon region

TUM scientists develop small molecule that may allow future patient-specific treatment of cancer tumours

Scientists outline molecular blueprints of tiny cellular 'nanomachine'

TSRI-led study finds potential new therapeutic approach for hard-to-treat breast cancers

Bitplane announces launch of Imaris 8.2 with ImarisLineage at ASCB 2015

Adaptimmune begins Phase I/II study of affinity enhanced T-cell therapy targeting MAGE-A10 in NSCLC patients

Combination therapy can help overcome endocrine resistance in women with advanced breast cancer

New discovery may soon make prostate cancer cells easier to destroy

Turing Pharmaceuticals emphasizes continued availability of Daraprim

Variant signs worldwide exclusive license and development agreement with L&F Research

Janssen collaborates with Bavarian Nordic to develop, commercialize vaccine for chronic HPV infections

UCL Cancer Institute win $200,000 CytoFLEX Flow Cytometer from Beckman Coulter

UCLA study may help resolve a neurological mystery

Synthetic biomaterial aids in regeneration of skin cells to improve wound healing

UB study traces how enigmatic molecules help cancer self-destruct

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

New test can help detect cancer and diabetes biomarkers in bloodstream

Novel drug candidate prevents nerve cell damage in mouse model of Parkinson's disease

What are the challenges of cell line development? eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence